- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05469373
ESIS in der pädiatrischen DRE
Elektrische Stimulation zur Anfallsinduktion bei pädiatrischer medikamentenrefraktärer Epilepsie (ESIS bei pädiatrischer DRE).
The main reason for this research study is to gain information about how the brain makes seizures by causing seizures using very small amounts of current, or electrical stimulation. Using small amounts of current to cause seizures (or stimulate) is not new at CCHMC - it is part of routine clinical practice for some patients at some electrodes.
This study differs from routine clinical care in that all study patients will undergo electrical stimulation in all or nearly all electrode contacts. The study team is doing this because there is promising data in adult patients that stimulating comprehensively (targeting all or nearly all of the electrode contacts) helps define the seizure network. Defining the seizure network in turn helps the medical team plan surgery. So far, there is not as much published data on seizure stimulation for pediatric patients.
This research study thus has the potential both to help individual patients (by providing specific information about your seizure networks) and to help pediatric patients with epilepsy in general (by increasing our understanding of stimulated seizures in children, teenagers and young adults).
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Epilepsy affects about 1% of the population, with roughly 30% of patients with epilepsy eventually developing drug-resistant epilepsy (DRE). Increasingly, surgery is pursued for DRE, yielding seizure freedom rates of 50-70%. However, accurate deduction of the epileptogenic zone (EZ) for surgical planning can be difficult in pediatric DRE, especially in those cases of multifocal seizures, as is often seen in Tuberous Sclerosis Complex (TSC), for example. Patients with multifocal epilepsy typically require a period of pre-surgical invasive EEG monitoring to record spontaneous seizures, the gold standard for EZ deduction. Unfortunately, the invasive monitoring process may be lengthy, costly and even fail to reveal a dominant EZ.
Electrical stimulation of induced seizures (ESIS) using stereo EEG (sEEG) has been shown to be a safe and valid adjunct for EZ delineation in adults with DRE. ESIS can be implemented within 1-2 days of electrode implantation, while the patient would otherwise be passively awaiting spontaneous seizures. ESIS typically induces habitual seizures with few side effects, and there is no data to suggest that ESIS inhibits spontaneous seizures or prolongs the otherwise clinically-indicated hospital stay. Crucially, published data show that induced seizures provide information about the EZ that is both convergent with and unique from that provided by spontaneous seizures. Despite these promising reports, ESIS is not widely integrated into pediatric DRE evaluation.
The overall objective is to improve methods of EZ identification in pediatric DRE patients with complex EZs, thereby increasing the likelihood of surgical candidacy for patients and ultimately improving surgical outcomes. In this protocol, investigators hypothesize that electrical stimulation of induced seizures (ESIS) is an effective adjunct for EZ delineation in children with DRE. To test this, the study will enroll n=86 patients with DRE undergoing sEEG evaluation aged 1-30 years. Based on the CCHMC epilepsy surgery program throughput, it is anticipated that this will include approximately n=36 patients with TSC and n=50 without TSC, which will provide the opportunity to compare the utility of this technique between patients with and without TSC. Patients will undergo ESIS using published Cincinnati Children's Hospital Medical Center (CCHMC) parameters with modifications. Gray and white matter contacts will be stimulated systematically. Safety, tolerability, yield, validity and parameter space will be examined.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Participants with drug-refractory epilepsy who receive care at or are referred into the CCHMC Comprehensive Epilepsy Center will comprise the targeted study population. Specifically, those patients who undergo phase I evaluations and are subsequently recommended for phase II evaluations at CCHMC will be identified as research study candidates.
Beschreibung
Inclusion Criteria:
- Diagnosis of drug-refractory epilepsy (DRE)
- 1-30 years of age
- recommended to undergo stereoencephalography (sEEG) at CCHMC
Exclusion Criteria:
- <1 and >30 years of age
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_ONLY
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety -- Occurrence of generalized, convulsive and prolonged seizures
Zeitfenster: Phase II epilepsy surgery testing
|
Evaluate the safety of ESIS in pediatric DRE patients. |
Phase II epilepsy surgery testing
|
|
Tolerability -- Quantify study withdrawal and patient/caregiver experience
Zeitfenster: during Phase II epilepsy surgery testing
|
Evaluate the tolerability of ESIS in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
|
Yield -- Rate of induction of habitual seizures
Zeitfenster: during Phase II epilepsy surgery testing
|
Evaluate the yield of ESIS in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
|
Clinical Validity
Zeitfenster: during Phase II epilepsy surgery testing and through study completion, an average of 1 year
|
Test the clinical validity of ESIS in pediatric DRE patients by examining the impact of occurance of induced seizures on surgical outcomes. |
during Phase II epilepsy surgery testing and through study completion, an average of 1 year
|
|
Predictors
Zeitfenster: during Phase II epilepsy surgery testing
|
Investigate the methodologic, anatomic, and patient-specific predictors of induced seizures in pediatric DRE patients. |
during Phase II epilepsy surgery testing
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Sarah Katie Ihnen, MD, PhD, Children's Hospital Medical Center, Cincinnati
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Neubildungen
- Genetische Krankheiten, angeboren
- Neurodegenerative Krankheiten
- Angeborene Anomalien
- Heredodegenerative Erkrankungen, Nervensystem
- Neoplastische Syndrome, erblich
- Neurokutane Syndrome
- Hamartom
- Neubildungen, mehrere primäre
- Fehlbildungen der kortikalen Entwicklung, Gruppe I
- Fehlbildungen der kortikalen Entwicklung
- Missbildungen des Nervensystems
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Arzneimittelresistente Epilepsie
- Tuberöse Sklerose
- Epilepsie
Andere Studien-ID-Nummern
- 2022-0020
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .